tradingview.comOCT 232 min read

Cantor Fitzgerald reiterates Overweight rating on Trulieve Cannabis, $15 price target

Cantor Fitzgerald maintained an Overweight rating on Trulieve Cannabis with a $15 price target, suggesting a 37.4% upside from the Oct 22 close. The firm cited Trulieve's strong operational infrastructure, market leadership, and growth potential, including regulatory catalysts.

Original reporting

tradingview.com

Published Oct 23, 2026, 10:23 AM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Oct 23, 2026, 10:32 AM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

Cantor Fitzgerald reiterates Overweight rating on Trulieve Cannabis, $15 price target — source image — Source · tradingview.com

Decision brief

The 30-second read

Med

Why it matters

The analyst's reiteration of Overweight and a $15 target may attract new buying, but investors should monitor regulatory developments in Texas.

Market read

A fresh analyst upgrade with a higher price target provides a short‑term catalyst for TRUV and may influence peer sentiment in the cannabis sector.

What to watch

Execution risk of expanding into adult‑use markets and the capital intensity of cultivation facilities.

Relevance 7/10Novelty 7/10Timing: pre‑market today

Background

Trulieve Cannabis (TRUV) operates 162 dispensaries in Florida and is a leading medical‑cannabis provider.

Market effects

Sector

May lift sentiment across the U.S. cannabis sector as analysts show confidence in medical‑cannabis operators.

Regional

Potentially benefits Florida‑focused cannabis stocks given Trulieve's strong presence in the state.

Global

Limited to U.S. cannabis equities; no broader macro impact.

Counterpoint

What could challenge this read

The rating could be premature if regulatory approvals in Texas stall, leaving the target overly optimistic.

Key entities

Analyst
Cantor Fitzgerald
Equity research firm issuing the rating.
Company
Trulieve Cannabis
U.S. medical cannabis operator.

Read at source ← All news

OCT 23

$TRLVMedAI 8/10

Cantor Fitzgerald reiterates Trulieve Cannabis stock Overweight rating

Cantor Fitzgerald reiterated an Overweight rating and $15.00 price target on Trulieve Cannabis (TRLV), citing its scaled, vertically integrated medical operations. The stock is up 43% over six months, trading at $10.92. Q2 2026 earnings beat estimates with $0.11 EPS, though revenue slightly missed at $271M. The firm noted the company's organized, scalable platform and expects profitability this year.

investing.com2 min

SEP 30

$TRLVHigh

Why is Trulieve Cannabis stock sliding today?

Trulieve Cannabis (TRLV) shares fell 6.5% in pre-market trading after announcing a licensing deal with Connected Cannabis, which investors reassessed for costs and risks. CEO Kim Rivers' share sale plan and institutional rebalancing added pressure. Q2 revenue was $271M, down 10% YoY, with a net loss. Broader market conditions offered no support.

investing.com1 min

SEP 29

$MSOSHigh

MSOS, TRLV Slide After Hours As DEA Judge Pauses Cannabis Rescheduling Case

MSOS, an ETF, and TRLV, one of its holdings, fell about 8-9% after hours as a federal judge paused a cannabis rescheduling case. The delay impacts investors' expectations for near-term changes to marijuana's legal status, which could affect the industry.

stocktwits.com2 min

AUG 29

$TRLVMed

Trulieve Cannabis (TRLV) Is Up 6.5% After ESOP-Linked US$55.5 Million Share Issuance - Has The Bull Case Changed?

Trulieve Cannabis (TRLV) issued 10 million shares worth $55.5 million in an ESOP-related offering, causing a 6.5% stock price increase. The company also authorized a $50 million share buyback program. Analysts project varying revenue and earnings forecasts for 2029, with some seeing significant upside and others a more pessimistic outlook. Q2 2026 sales declined year over year, and net loss widened, keeping margin trends and capital deployment in focus.

simplywall.st3 min

AUG 29

$ZIMMedAI 8/10

Dow, S&P 500, Nasdaq Futures Rise On AI, Fed Watch After Holiday Break: Why ZIM, AAPL, TCNNF, DIS Kept Traders On Edge Today

U.S. stock futures rose late Monday, with Nasdaq up 0.01%, S&P 500 up 0.1%, and Dow up 0.05%. Investors focused on AI disruption, Fed rate path, and inflation data. ZIM agreed to a $4.2B acquisition by Hapag-Lloyd at $35 per share. AAPL announced a March 4 event, potentially featuring new products. TCNNF and DIS also drew attention.